• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中欧早发性和家族性帕金森病患者中LRRK2基因p.L1795F变异的患病率及临床特征

Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early-Onset and Familial Parkinson's Disease.

作者信息

Ostrozovicova Miriam, Tamas Gertrud, Atputhavadivel Agsha, Dusek Petr, Grofik Milan, Han Vladimir, Holly Petr, Jech Robert, Kalinova Katarina, Klivenyi Peter, Kovacs Norbert, Kulcsarova Kristina, Kurca Egon, Lackova Alexandra, Lee Hamin, Lewis Patrick, Magocova Veronika, Marekova Maria, Murphy David, Nagano Ai, Necpal Jan, Pinter David, Rabajdova Miroslava, Ruzicka Evzen, Serranova Tereza, Smilowska Katarzyna, Soos Krisztina, Straka Igor, Svorenova Tatiana, Valkovic Peter, Zarubova Katerina, Gdovinova Zuzana, Houlden Henry, Rizig Mie, Skorvanek Matej

机构信息

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.

Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

出版信息

Mov Disord Clin Pract. 2025 Mar 22. doi: 10.1002/mdc3.70045.

DOI:10.1002/mdc3.70045
PMID:40119633
Abstract

BACKGROUND

Leucine-rich repeat kinase 2 (LRRK2) p.L1795F variant was proposed as a genetic risk factor for Parkinson's disease (PD). However, its prevalence, phenotype, and origin remain unknown.

OBJECTIVE

The aim was to evaluate the frequency and phenotype of p.L1795F in early-onset PD (EOPD) and familial PD compared to healthy controls (HC) in Central Europe.

METHODS

Whole-exome sequencing was used to screen 219 EOPD and familial PD patients of Central Europeans compared to HC. Sanger sequencing assessed segregation. Detailed clinical phenotype was evaluated for all positive carriers.

RESULTS

p.L1795F was identified in 1.37% (3/219) and 3.23% of familial cases (3/93), with no carriers among HCs (0/303). Segregation analysis confirmed association with PD. Carriers were traced to the eastern Slovak-Hungarian region. It also appears to be associated with a more aggressive phenotype.

CONCLUSION

Our data indicate that p.L1795F contributes to PD in Central Europe. Further exploration in larger cohorts is warranted to establish its contribution to global PD risk.

摘要

背景

富含亮氨酸重复激酶2(LRRK2)p.L1795F变异被认为是帕金森病(PD)的一个遗传风险因素。然而,其患病率、表型及起源仍不清楚。

目的

旨在评估中欧早发性帕金森病(EOPD)和家族性帕金森病中p.L1795F相对于健康对照(HC)的频率和表型。

方法

采用全外显子组测序对219例中欧EOPD和家族性帕金森病患者与健康对照进行筛查。桑格测序评估分离情况。对所有阳性携带者评估详细的临床表型。

结果

在1.37%(3/219)的病例及3.23%的家族性病例(3/93)中鉴定出p.L1795F,健康对照中无携带者(0/303)。分离分析证实其与帕金森病相关。携带者追溯至斯洛伐克东部-匈牙利地区。它似乎也与更具侵袭性的表型相关。

结论

我们的数据表明p.L1795F在中欧对帕金森病有影响。有必要在更大队列中进一步探索以确定其对全球帕金森病风险的影响。

相似文献

1
Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early-Onset and Familial Parkinson's Disease.中欧早发性和家族性帕金森病患者中LRRK2基因p.L1795F变异的患病率及临床特征
Mov Disord Clin Pract. 2025 Mar 22. doi: 10.1002/mdc3.70045.
2
an adaptive immune response gene, is associated with Parkinson's disease risk and age at onset.一种适应性免疫反应基因,与帕金森病风险及发病年龄相关。
J Parkinsons Dis. 2024 Nov;14(8):1575-1583. doi: 10.1177/1877718X241296015. Epub 2024 Dec 1.
3
p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe.p.L1795F LRRK2变异是中欧帕金森病的常见病因。
Res Sq. 2024 May 29:rs.3.rs-4378197. doi: 10.21203/rs.3.rs-4378197/v1.
4
Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease.与帕金森病相关的新发现的 LRRK2 变异体的临床特征和病理生理学特性。
Neurobiol Dis. 2024 Sep;199:106571. doi: 10.1016/j.nbd.2024.106571. Epub 2024 Jun 18.
5
Clinical feature and alpha-synuclein level of restless legs syndrome with leucine-rich repeat kinase 2 encoding gene mutation.携带富含亮氨酸重复激酶2编码基因突变的不宁腿综合征的临床特征及α-突触核蛋白水平
Parkinsonism Relat Disord. 2025 Sep;138:107944. doi: 10.1016/j.parkreldis.2025.107944. Epub 2025 Jul 7.
6
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.帕金森病变异检测与披露:北美研究项目“PD基因计划”
Brain. 2024 Aug 1;147(8):2668-2679. doi: 10.1093/brain/awae142.
7
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.基因靶向试验时代基因检测的相关性:罗斯托克帕金森病研究
Brain. 2024 Aug 1;147(8):2652-2667. doi: 10.1093/brain/awae188.
8
Association of LRRK2 R1628P variant with Parkinson's disease in Kinh Vietnamese: a cross-sectional study.越南京族中LRRK2基因R1628P变异与帕金森病的关联:一项横断面研究。
Neurogenetics. 2025 Jul 31;26(1):56. doi: 10.1007/s10048-025-00840-9.
9
Widespread distribution of α-synuclein oligomers in LRRK2-related Parkinson's disease.α-突触核蛋白寡聚体在与富亮氨酸重复激酶2(LRRK2)相关的帕金森病中的广泛分布。
Acta Neuropathol. 2025 May 2;149(1):42. doi: 10.1007/s00401-025-02872-9.
10
Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.非甾体抗炎药的使用与 LRRK2 帕金森病的外显率。
Mov Disord. 2020 Oct;35(10):1755-1764. doi: 10.1002/mds.28189. Epub 2020 Jul 14.

本文引用的文献

1
Analysis of rare Parkinson's disease variants in millions of people.对数百万人中的罕见帕金森病变体进行分析。
NPJ Parkinsons Dis. 2024 Jan 8;10(1):11. doi: 10.1038/s41531-023-00608-8.
2
Central European Group on Genetics of Movement Disorders.中欧运动障碍遗传学小组
Eur J Neurol. 2024 Apr;31(4):e16165. doi: 10.1111/ene.16165. Epub 2023 Dec 7.
3
Predicting variant pathogenicity with AlphaMissense.使用AlphaMissense预测变异致病性。
Nat Rev Genet. 2023 Dec;24(12):804. doi: 10.1038/s41576-023-00668-9.
4
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.帕金森病相关的 100 个 LRRK2 变异对激酶活性和微管结合的影响。
Biochem J. 2022 Sep 16;479(17):1759-1783. doi: 10.1042/BCJ20220161.
5
Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review.LRRK2 变异体在帕金森病中的流行情况:全面综述。
Parkinsonism Relat Disord. 2022 May;98:103-113. doi: 10.1016/j.parkreldis.2022.05.012. Epub 2022 May 25.
6
Structural analysis of the full-length human LRRK2.全长人 LRRK2 的结构分析。
Cell. 2021 Jun 24;184(13):3519-3527.e10. doi: 10.1016/j.cell.2021.05.004. Epub 2021 Jun 8.
7
LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study.中欧帕金森病患者的LRRK2突变:一项病例对照研究。
Parkinsonism Relat Disord. 2021 Feb;83:110-112. doi: 10.1016/j.parkreldis.2020.12.021. Epub 2021 Jan 11.
8
LRRK2 in Parkinson disease: challenges of clinical trials.LRRK2 在帕金森病中的作用:临床试验面临的挑战。
Nat Rev Neurol. 2020 Feb;16(2):97-107. doi: 10.1038/s41582-019-0301-2. Epub 2020 Jan 24.
9
The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials.基因检测在匈牙利队列早发性帕金森氏症疾病临床实践与研究中的作用:基因咨询面临的挑战日益增加,临床试验分层的机会得到改善
Front Genet. 2019 Oct 31;10:1061. doi: 10.3389/fgene.2019.01061. eCollection 2019.
10
Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.帕金森病中五个孟德尔基因及全基因组关联研究中顶级基因的重测序分析。
Mol Neurodegener. 2016 Apr 19;11:29. doi: 10.1186/s13024-016-0097-0.